Consensus ESG Ratings
Member Sign In
ESG News For Ionis Pharmaceuticals, Inc.
These sites contributed news to this page:
-
Positive Clinical Observations from n-Lorem Treated, KIF1A Nano-rare Patient Published in Nature Medicine
Case study, published in Nature Medicine, details improvements in nano-rare patient, Susannah’s seizure severity, neurologic function and quality of life -
n-Lorem and The Wolverine Foundation Collaborate to Support the Discovery and Development of Personalized ASO Medicines for Nano-rare Patients
n-Lorem received a $3 million donation to support its efforts in ASO research and discovery -
Parexel and n-Lorem Foundation Partner to Support Development of New Investigational Therapies for Nano-rare Patients
Parexel to provide clinical operations, real-world data solutions and expertise including medical and regulatory alongside innovative clinical research tools that will significantly enhance and streamline n-Lorem’s therapeutic development efforts -
n-Lorem Foundation Announces Partnership with Nitto Avecia to Strengthen Development of Personalized Medicines for Patients with Ultra-Rare Diseases
World’s largest oligonucleotide manufacturer provides drug ingredients and financial donation to support development of experimental antisense medicines, helping n-Lorem reach more patients n-Lorem’s third partnership in the last quarter boosts resources to assist patients with ultra-rare mutations -
Global Genes Launches RARE Health Equity Council to Help Build a More Inclusive Healthcare System and Improve Access and Experiences for Underserved Patients With Rare Diseases
Global Genes launches RARE Health Equity Council to help build inclusive healthcare system and improve access for underserved rare disease patients.